XNASIMTX
Market cap843mUSD
Dec 24, Last price
6.71USD
1D
3.21%
1Q
-39.47%
IPO
-53.02%
Name
Immatics NV
Chart & Performance
Profile
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
Income | ||||||
Revenues | 53,997 -68.76% | 172,831 397.17% | 34,763 11.23% | |||
Cost of revenue | 275,524 | 249,682 | 208,956 | |||
Unusual Expense (Income) | ||||||
NOPBT | (221,527) | (76,851) | (174,193) | |||
NOPBT Margin | ||||||
Operating Taxes | 4,552 | 1,726 | ||||
Tax Rate | ||||||
NOPAT | (221,527) | (81,403) | (175,919) | |||
Net income | (96,994) -358.55% | 37,514 -139.46% | (95,061) -58.55% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 90,404 | 134,484 | 94 | |||
BB yield | -10.66% | -22.43% | -0.01% | |||
Debt | ||||||
Debt current | 2,604 | 2,159 | 2,711 | |||
Long-term debt | 28,200 | 26,965 | 16,995 | |||
Deferred revenue | 75,759 | 48,225 | ||||
Other long-term liabilities | 115,531 | 42 | 68 | |||
Net debt | (395,091) | (333,081) | (125,411) | |||
Cash flow | ||||||
Cash from operating activities | 18,228 | 100,131 | (81,784) | |||
CAPEX | (30,799) | (6,215) | (5,657) | |||
Cash from investing activities | (31,388) | (209,791) | 7,493 | |||
Cash from financing activities | 84,516 | 123,710 | (2,613) | |||
FCF | (252,093) | (87,404) | (182,391) | |||
Balance | ||||||
Cash | 425,895 | 362,205 | 145,117 | |||
Long term investments | ||||||
Excess cash | 423,195 | 353,563 | 143,379 | |||
Stockholders' equity | (598,082) | (501,013) | (541,129) | |||
Invested Capital | 954,099 | 796,816 | 621,578 | |||
ROIC | ||||||
ROCE | ||||||
EV | ||||||
Common stock shares outstanding | 80,547 | 68,825 | 62,913 | |||
Price | 10.53 20.90% | 8.71 -35.19% | 13.44 24.56% | |||
Market cap | 848,157 41.49% | 599,465 -29.10% | 845,550 63.25% | |||
EV | 453,066 | 266,384 | 720,139 | |||
EBITDA | (214,293) | (69,884) | (168,933) | |||
EV/EBITDA | ||||||
Interest | 831 | 8,279 | 1,726 | |||
Interest/NOPBT |